Abstract: The present invention concerns the use of methods and compositions for the treatment of cancer and other hyperproliferative diseases. In certain embodiments, methods are described for the treatment of cancer and/or hyperproliferative diseases by administration of compositions containing at least one platinum complex alone or in combination with a modulator of glutathione. In particular, the methods may be used to treat cisplatin or carboplatin resistant tumor cells.
Type:
Application
Filed:
September 5, 2003
Publication date:
May 20, 2004
Applicant:
Board of Regents, The University of Texas System
Abstract: An energizing and rehydrating composition for oral administration to be used to enhance physical performance and increase resistance to fatigue, both in humans and in animals, helping the body to quickly restore energy lost in intense physical activity and to replace electrolytes lost through sweating; the product containing the following fundamental ingredients: one or more magnesium salts of a phosphorylated carbohydrate (in particular, fructose-1,6-diphosphate magnesium salt), one or more calcium salts of a phosphorylated carbohydrate (in particular, fructose-1,6-diphosphate calcium salt) and ribose. Other preferred ingredients of the energy supplement are an organic salt of chromium (in particular, chromium picolinate), maltodextrin and maltose. The invention also concerns a multivitamin-mineral drink containing an energy supplement of the composition described, dissolved in water.
Abstract: This invention is directed to a multi-vitamin and mineral supplement tailored to men and post-menopausal women, pre-menopausal women, and athletes which supplies the right amount of the right micronutrients at the right time to assure adequate intake of micronutrients needed for disease prevention and protection against nutritional losses and deficiencies due to lifestyle factors and common inadequate dietary patterns. The multi-vitamin and mineral supplement is comprised of vitamin A, vitamin C, vitamin D, vitamin E, vitamin K, vitamin B1, vitamin B2, niacinamide, vitamin B6, vitamin B12, biotin, pantothenic acid, iron, iodine, magnesium, zinc, selenium, copper, chromium, potassium, choline, lycopene, and co-enzyme Q-10.
Type:
Application
Filed:
October 25, 2002
Publication date:
April 29, 2004
Inventors:
Kenneth H. Cooper, Ishwarlal Jialal, Scott Montgomery Grundy, Walter Churchill Willett, Jacob Selhub
Abstract: A compound of the formula
wherein the substituents are defined as in the specification and their pharmaceutically acceptable salts having NOS and ROS activity.
Type:
Grant
Filed:
April 2, 2003
Date of Patent:
April 27, 2004
Assignee:
Societe de Conseils de Recherches et d'Applications
Scientifiques (S.C.R.A.S.)
Abstract: A zinc(II) complex which is lowly toxic, has high insulin-like activity, and is effectively usable as a hypoglycemic agent for the prevention or treatment of diabetes; a hypoglycemic agent containing the complex; a medicinal preparation which contains the complex and is useful as a preventive/remedy for diabetes; and a food containing the complex, such as a health food or supplementary health food. The hypoglycemic agent contains an organic zinc(II) complex having as a ligand a compound selected among aminoalkylpyridines, bis-optically active amino acids, bisaminoalkylcarboxylic acids, oligopeptides, oligopseudopeptides, di-substituted aminocarboxylic acids, &agr;- and &bgr;-hydroxycarboxylic acids, vitamins, glutamine derivatives, etc.
Abstract: A new class of polychelants, their chelates with metal ions and their physiologically acceptable salts, useful, either as they are or in association or formulation with other components, for diagnostic imaging as general or specific contrast agents for specific tissues, organs or body compartments.
Abstract: Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and/or known anti-inflammatory drugs, such as aspirin.
Type:
Application
Filed:
February 3, 2003
Publication date:
April 8, 2004
Inventors:
Werner Haas, Carlos Romao, Beatriz Roya, Ana Cristina Fernandes, Isabel Goncalves
Abstract: This invention provides a class of androgen receptor targeting agents (ARTA). The agents define a new subclass of compounds, which are selective androgen receptor modulators (SARM). Several of the SARM compounds have been found to have an unexpected androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. Other SARM compounds have been found to have an unexpected antiandrogenic activity of a nonsteroidal ligand for the androgen receptor.
Type:
Application
Filed:
June 17, 2003
Publication date:
April 8, 2004
Inventors:
James T. Dalton, Duane D. Miller, Craig A. Marhefka, Wenqing Gao
Abstract: Disclosed is a method for delivering excess zinc to eukaryotic cells to inhibit the metabolism of the cell, the method comprising treating the cells with a zinc ionophoric that is capable of delivering a zinc ion across a cellular membrane wherein the minimum inhibitory concentration (MIC) of the zinc ionophoric material is less than about 500 ppm. Further disclosed is a method for delivering excess zinc to eukaryotic cells to inhibit the metabolism of the cell, the method comprising treating the cells with a zinc ionophoric material that is capable of delivering a zinc ion across a cellular membrane wherein the zinc ionophoric material is in combination with a zinc containing material and further wherein there is an increase in an intracellular zinc level by 1.5 fold more than would occur in the absence of the zinc ionophoric material.
Type:
Application
Filed:
March 18, 2003
Publication date:
March 25, 2004
Inventors:
James R. Schwartz, George Polson, Patricia A. Turley, John D. Nelson, David F. Gavin, Katherine P. Roberts, Carl Hinz Margraf, David Joseph Kaufman, Randall Glenn Marsh
Abstract: The invention relates to a pharmaceutical composition, a therapeutic combination product and a kit comprising a sterically hindered platinum coordination compound and a non-platinum based anti-cancer agent and a pharmaceutically-acceptable carrier or diluent; to the use thereof for the manufacture of a medicament for inhibiting the growth of tumour cells in a human afflicted therewith; to a method of inhibiting the growth of tumour cells in a human afflicted therewith which comprises administering to such human an effective tumour cell growth inhibiting amount of such a therapeutic combination product or of a pharmaceutical composition of the invention; in particular when the sterically hindered platinum coordination compound is (SP-4-3)-(cis-amminedichloro-[2-methylpyridine]platinum (II), or a pro-drug thereof, and the non-platinum based anti-cancer agent is selected from Taxol, Gemcitabine, Navelbine, Doxil, 5-FU and Taxotere.
Type:
Application
Filed:
September 4, 2003
Publication date:
March 18, 2004
Inventors:
Mark Peart Smith, Trevor Charles Stephens
Abstract: The present invention relates to a method for the large scale preparation of a viscous pharmaceutical or veterinary composition comprising a heat-sensitive component and, in particular, to a method of preparing an ointment.
Abstract: A method for separating and purifying the active hematinic species (AHS) present in iron-saccharidic compositions, including AHS such as sodium ferric gluconate complex, ferric hydroxide-sucrose complex and ferric saccharate complex and others of similar form and function. The method separates the AHS from one or more excipients and, preferably, lyophilizes the separated AHS. Separation of the AHS permits its analytical quantification, further concentration, purification and/or lyophilization as well as preparation of new and useful products and pharmaceutical compositions.
Abstract: Compositions in solid form, such as powders, comprising a mixture of a ferrous salt and a hydroxypyrone may be used to increase the level of iron in a patient's bloodstream or to treat and/or prevent gastrointestinal infection.
Abstract: The invention relates to ligand complexes characterised by the presence of a piperazineNONOate residue with metal cations where the cations derive from a transition metal or zinc in a stable oxidation state. These complexes are nitric oxide donors and exert an endothelio-protective effect on the coronary district and stimulate re-endothelialization and angiogenesis processes. The invention comprises a preparation process and the therapeutic use of said compounds.
Abstract: The invention provides mitochondrially targeted antioxidant compounds comprising a lipophilic cation moiety covalently coupled to an antioxidant moiety which is either a superoxide dismutase (SOD) mimetic or a glutathione peroxidase mimetic. These compounds can be used to treat patients who would benefit from the reduction of oxidative stress.
Type:
Application
Filed:
August 12, 2002
Publication date:
February 12, 2004
Applicants:
Medical Research Council, University of Otago
Abstract: Compounds which may be used in the treatment and/or prevention of cancer have the formula (I): wherein R1 and R2 together with the ring to which they are bound represent a saturated or unsaturated carbocyclic or heterocyclic group.
Type:
Application
Filed:
August 15, 2003
Publication date:
February 12, 2004
Inventors:
Robert Edward Morris, Peter John Sadler, Duncan Jodrell, Haimei Chen
Abstract: The invention relates to a method for producing special transition metal compounds, to novel transition metal compounds and to the use of the same for the polymerisation of olefins.
Abstract: The present invention discloses an aqueous phenolates-containing liquid formulation having a solidification point of less than or equal to −10° C.
Abstract: Novel organic arsonic compounds are described as tumor inhibiting, and cancer treating compounds. Methods and compositions for inhibiting tumor cells and treating cancer are also provided.
Abstract: The present invention relates to pharmaceutical compositions comprising an atypical antipsychotic agent in combination with a chromium salt, which are used for treating atypical depression, as well as minimizing side effects in a patient taking an atypical antipsychotic agent.
Abstract: Antimicrobial compositions based on haloalkynyl active ingredients that are chemically stable in the presence of chelated metal ion are disclosed. Particularly preferred is the use of metal ion chelating agents based on selected amine compounds that provide the metal ion in a form sufficient to provide stability to other antimicrobial components in the aqueous composition, but without concurrently degrading the antimicrobial effectiveness of the haloalkynyl active ingredient.
Type:
Application
Filed:
June 24, 2003
Publication date:
January 22, 2004
Inventors:
Beverly Jean El A'mma, Susan Lynn Nagahashi
Abstract: Methods for promoting healthy body weight and improving a variety of related physiological factors, including serum serotonin levels, serum leptin levels, fat oxidation, cholesterol levels, and body mass index, in persons or other mammals, include administering to those persons or other mammals effective amounts of hydroxycitric acid or a combination of hydroxycitric acid, chromium and gymnemic acid, which work synergistically to further to promote healthy body weight and improve these physiological factors.
Abstract: The present invention relates to the use of water-soluble photo-stable silver thiosulfate ion complexes that are antimicrobially active and inhibit the activity of metalloproteinases. The present invention describes incorporation of these complexes into medical devices and/or wound dressings to prevent or treat symptomology related to microbial infections and/or conditions of excessive tissue destruction. In particular, these complexes may be useful in the treatment of rheumatoid arthritis and/or osteoarthritis in the prevention and treatment of articular bone joint degradation and subsequent reductions in joint swelling and pain.
Abstract: Compounds that demonstrate chelation affinity and selectivity for first transition series elements are administered to patients suffering from such conditions as ischemia, prolonged seizures and trauma to provide neuroprotection, cardioprotection, or both. These compounds when administered form complexes with chelatable iron and copper cations and thereby mitigate the ability of these cations to catalyze Haber-Weiss reactions that form toxic hydroxy free radicals that cause tissue injury. These compounds also form complexes with chelatable zinc cations thereby inhibiting the cytotoxicity associated with excess chelatable zinc.
Type:
Application
Filed:
June 13, 2002
Publication date:
January 8, 2004
Applicants:
CONCAT, LTD. a California Limited Partnership, CHELATOR LLC., a Delaware corporation
Abstract: Vanadium (IV) complexes containing a substituted or unsubstituted catecholate ligand, and the spermicidal activity of such compounds. Preferred compounds are vanadocene (IV) complexes containing alkyl substituted catecholate ligands.
Type:
Grant
Filed:
July 23, 2002
Date of Patent:
December 23, 2003
Assignee:
Parker Hughes Institute
Inventors:
Phalguni Ghosh, Faith M. Uckun, Osmond D′Cruz
Abstract: Methods, compositions, and kits for reducing a microbial population on a surface are provided. The microbial populations which can be treated using the methods, compositions, and kits of the present invention include prokaryotic, viral, and protozoan populations. The methods, compositions, and kits of the present invention have a number of uses in the fields of food production and medicine.
Type:
Application
Filed:
June 17, 2003
Publication date:
December 18, 2003
Applicant:
SureCide Technologies, LLC
Inventors:
Kenneth Beckman, John L. Grimsich, Christopher Hawk, Frank Swenson, David Tyler
Abstract: Dithiocarbamate, particularly tetraethylthiuram disulfide, and thiocarbamate anions strongly inhibit the growth of cancer cells of a variety of cell types. Such inhibitory effect is enhanced by heavy metal ions such as copper ions, cytokines and ceruloplasmin. A method is presented for using tetraethylthiuram disulfide to reduce tumor growth, and to potentiate the effect of other anticancer agents.
Type:
Application
Filed:
March 3, 2003
Publication date:
December 11, 2003
Applicant:
Charlotte-Mecklenburg Hospital Authority d/b/a Carolinas Medical Center
Abstract: A novel antidandruff conditioning shampoo comprising a cleansing surfactant, a water-insoluble antidandruff and/or anti-itching agent, a conditioning agent, a natural oil, and a suitable carrier, and a method of treating hair are disclosed. The shampoo compositions effectively suspend the water-insoluble hair treating compound, effectively cleanse the hair and effectively deliver the water soluble and water insoluble hair-treating compounds to the hair and scalp and also effectively condition the hair.
Abstract: Certain Lp-Mn+ metal complexes are well suited for promoting desquamation of the skin and/or stimulating epidermal renewal, for example preventing or treating dry skin and/or cutaneous signs of aging and/or pigmentation of the skin and/or acne-prone greasy skin; too, these are also suited for preventing/treating hyperkeratosis-induced skin disordes.
Abstract: Multivitamin/Multimineral supplements are provided for supplementing iron and desirable nutrients in the diet of mammals. The supplements include an iron-amino acid chelate, a form of iron more bioavailable than traditional iron salts. The supplements may further include a pharmaceutically accepted salt form of iron as well as other nutritional vitamins and minerals. The supplements are useful for providing iron for pregnant and lactating females as well as for persons suffering from anemia.
Type:
Application
Filed:
February 27, 2003
Publication date:
November 6, 2003
Applicant:
Integrity Pharmaceutical Corporation
Inventors:
Prasad Nidamarty, William R. Hurd, Roland J. Bydlon, William C. Williams, Michael Dempsey, Amy Erbskorn
Abstract: Vanadium compounds as anti-proliferative agents. These compounds act to disrupt mitotic and meiotic spindle formation and thus are useful to prevent cell mitosis (proliferation) and meiosis.
Abstract: In accordance with the present invention, there are provided methods for the in vivo reduction of free radical levels in mammalian subjects in need thereof. In contrast to the inhibitory approach described in the prior art (i.e., wherein the function of the species responsible for free radical production is inhibited), the present invention employs a scavenging approach whereby overproduced free radical is bound in vivo to a suitable free radical scavenger. An exemplary free radical scavenger contemplated for use in the practice of the present invention is a dithiocarbamate-ferrous iron complex. This complex binds to free radicals, forming a stable, water-soluble free radical-containing complex. When administered to a subject afflicted with a disorder associated with free radical overproduction (e.g.
Abstract: Prophylactic treatment to reduce the incidence of common cold using formulations of zinc compounds with selected amino acids is described. The administration of such formulations to healthy individuals resulted in a statistically significant reduction in the incidence of common colds in healthy patients.
Type:
Application
Filed:
April 23, 2002
Publication date:
October 23, 2003
Inventors:
Richard A. Rosenbloom, Charles A. Phillips
Abstract: The invention relates to a biocidal composition which can be added to materials which can be attacked by harmful micro-organisms, containing pyrithione as a biocidal active ingredient. The biocidal composition is characterised in that it contains 2-alkyl isothiazoline-3-one as another biocidally active ingredient. The active ingredients of the biocidal composition behave synergistically and are ideally suitable for controlling bacteria, fungus and algae.
Type:
Application
Filed:
February 10, 2003
Publication date:
October 23, 2003
Inventors:
Dagmar Antoni-Zimmermann, Rudiger Baum, Thomas Wunder, Hans-Jurgen Schmidt
Abstract: The present invention is directed to complexes comprising iron in the ferric state and a hydroxypyrone. The present invention is also directed to methods of making such complexes and to the use of such complexes in the treatment and prevention of iron deficiency disorders including iron deficiency anaemia.
Type:
Grant
Filed:
October 25, 2001
Date of Patent:
October 21, 2003
Assignee:
Vitra Pharmaceuticals, Ltd.
Inventors:
Michael Arthur Stockham, Robert Charles Hider
Abstract: Peptide compositions and methods for inhibiting and controlling the growth of microbes using peptides possessing antimicrobial activity are described. The composition comprises at least one antimicrobial peptide in combination with at least one biocide, germicide, preservative or antibiotic. The method comprises administering an amount of the peptide composition effective for the prevention, inhibition or termination of microbes in industrial and clinical settings.
Abstract: Disinfectant formulations are described which are preferably ecologically friendly and non-toxic to mammals and plants, and are highly effective against a broad spectrum of detrimental pathogenic microorganisms. The microbicidal formulation contains complexes having at least one metal ion which is microbicidal to at least one microorganism and potassium sodium tartrate in some form. When potassium sodium tartrate is used with these metal ions, it enhances the complex-forming properties of such metal complexes while concurrently increases their efficacy and potency at the same level of metal ion concentrations. These microbicidal formulations can be diluted in suitable proportions into aqueous systems to produce the desired dosages for each individual case, depending on the level and the severity of the contamination. The microbicidal formulations can be applied by conventional methods, e.g., spraying, soaking, fogging, impregnation, and the like.
Abstract: Compositions for pharmaceutical and other uses comprising clear aqueous solutions of bile acids which do not form any detectable precipitates over selected ranges of pH values of the aqueous solution and methods of making such solutions. The compositions of the invention comprise water; a bile acid in the form of a bile acid, bile acid salt, or a bile acid conjugated with an amine by an amide linkage; and either or both an aqueous soluble starch conversion product and an aqueous soluble non-starch polysaccharide. The composition remains in solution without forming a precipitate over a range of pH values and, according to one embodiment, remains in solution for all pH values obtainable in an aqueous system. The composition, according to some embodiments, may further contain a pharmaceutical compound in a pharmaceutically effective amount. Non-limiting examples of pharmaceutical compounds include insulin, heparin, bismuth compounds, amantadine and rimantadine.
Abstract: A therapeutic agent delivery composition containing a functional buffer system for facilitating absorption of pilocarpine in the buccal cavity. More particularly, the composition is used to raise the pH of the buccal cavity so that the pilocarpine agent is delivered in a lipophilic form capable of crossing the buccal membrane. The delivery composition raises the pH of the buccal cavity through the implementation of a buffer system, which comprises a combination of two or more buffer agents. The agents of the buffer system are combined in a manner where the stronger basic agent is at relatively larger levels than that of a corresponding weaker base. The delivery composition may be administered as a chewing gum, where the pilocarpine is effectively absorbed in about 5 minutes after the onset of chewing.
Abstract: A stabilised composition having antibacterial, antiviral and/or antifungal activity, said composition comprising silver ions and a ligand, characterised in that the composition comprises a complex of silver and a ligand selected from the group consisting of 5,5-disubstituted hydantoins in which the substituents do not comprise conjugated unsaturated bonds and barbituric acid and derivatives thereof stabilising silver ions against reduction to free silver in a hydrophilic environment, and that the composition has a solubility in water higher than 10 mg Ag/l is stable during sterilisation and retains the activity without giving rise to darkening or discoloration of the dressing during storage.
Abstract: A treatment for HIV, AIDS, and AIDS related diseases and compounds for use therewith are described. The compounds treat HIV, AIDS, and AIDS related diseases by inhibiting or preventing the virus from undergoing reverse transcription, post reverse transcription, integration, and/or post integration. The compounds also display activity against latently infected cells. In particular, the compounds each contain strontium; iodine; ascorbic acid; and a diamagnetic ion, either zinc, bismuth, or potassium.
Abstract: The present invention describes platinum (II) compounds and compositions useful for treating a subject with a tumor and/or inducing apoptosis in a population of cells. The present invention also describes pharmaceutical compositions containing the aforementioned inventive compound(s) in combination with a pharmaceutically acceptable carrier. Additionally, the invention further provides a method of inducing apoptosis in a population of cells and a method of treating a subject with a tumor, wherein the method comprises administering to the subject a therapeutically effective amount of the aforementioned compound(s) or composition(s).
Abstract: A pharmaceutical formulation having improved bioavailability and bioequivalence includes particles of amorphous and/or crystalline atorvastatin that have a particle size (d90) less than 150 &mgr;m and a mean particle size (d50) of the atorvastatin particles that is between approximately 5 and 50 &mgr;m. The atorvastatin can be one or more of atorvastatin calcium, atorvastatin magnesium, atorvastatin aluminum, atorvastatin iron, and atorvastatin zinc. The formulations of atorvastatin can be stabilized by mixing atorvastatin with an alkali metal salt additive at between approximately 1.2% and less than 5% w/w of the formulation.
Type:
Application
Filed:
February 14, 2003
Publication date:
September 18, 2003
Inventors:
Romi Barat Singh, Pananchukunnath Manoj Kumar, Rajiv Malik
Abstract: The novel active compound combinations of 5,7-dichloro-4-(4-fluoro-phenoxy)-quinoline of the formula
and the active compounds of groups (1) to (8) listed in the description have very good fungicidal properties.
Type:
Grant
Filed:
January 16, 2002
Date of Patent:
September 16, 2003
Assignee:
Bayer Aktiengesellschaft
Inventors:
Stefan Dutzmann, Klaus Stenzel, Astrid Mauler-Machnik, Ulrike Wachendorff-Neumann
Abstract: This invention relates generally to the production and use of inorganic-polymer complexes for the controlled release of compounds including medicinals. Advantageously, the inorganic used is calcium sulfate.
Abstract: A dermal agent for preventing or treating acne, comprising an ascorbic acid derivative which liberates in vivo ascorbic acid, and a zinc salt or comprising a zinc salt of the ascorbic acid-2-phosphate, and a composition comprising tretinoin and an ascorbic acid derivative or a salt thereof, relieving the irritation of tretinoin by using the dermal agent and tretinoin in combination.
Abstract: A method for reducing alcohol desire or dependency in a human can comprise the steps of administering a chelate or a combination of chelates to a human having alcohol dependency symptoms or an unwanted desire for alcohol. Ligands that can be used include carnitine, naturally occurring amino acids, and various thiamine molecules. Metals that can be used include nutritionally relevant metals, including copper, zinc, and manganese, to name a few.
Type:
Application
Filed:
November 26, 2002
Publication date:
August 21, 2003
Applicant:
Albion International, inc.
Inventors:
H. DeWayne Ashmead, R. Charles Thompson
Abstract: Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble polymer such as poly-glutamic acid, poly-aspartic acid or poly-lysine. Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis. Other embodiments include the coating of implantable stents for prevention of restenosis.
Type:
Application
Filed:
December 5, 2002
Publication date:
August 7, 2003
Applicant:
PG-TXL Company, L.P.
Inventors:
Chun Li, Sidney Wallace, Dong-Fang Yu, David J. Yang